

Introduction

The identification of clinically relevant biomarkers for neurodegenerative disorders is critical to the development of better therapeutic options and improved patient outcomes. Highly sensitive, multiplexed analysis of both neuro-specific proteins and the inflammatory response from blood and CSF provides scientists the power to detect important biomarkers such as pTau217, GFAP and

NFL, as well as measure changes in the key hallmarks of CNS disease. The NULISAseq CNS Disease Panel 120 provides robust analysis of 120+ proteins using just 10µL of sample (25µL input including dead volume) to support biomarker discovery and validation studies.

NULISA™ Technology

NULISAseq is a sandwich immunoassay in which two target specific antibodies, conjugated with unique oligonucleotide tags, bind and form a complex with the specific protein in solution. The resulting immunocomplex is purified in sequential capture and release steps to remove background and unbound antibodies. Successful formation of the immunocomplex brings the two oligonucleotide tags into proximity for a ligation reaction and amplification. The resulting unique oligonucleotide reporters containing both target and sample information are then pooled to a library for analysis on an NGS sequencer. The assay protocol is fully automated on the ARGO HT System and data is analyzed using the NULISA Analysis Software. More details on the assay protocol can be found [here](#).



Data Normalization & Calculation of NULISA Protein Quantification (NPQ) Values

NULISA Protein Quantification (NPQ) units are log₂-scale values used to quantify relative protein abundances. NPQ is derived from the raw sequencing reads using the following normalization and transformation steps. First, to control for intra-plate well-to-well variation, the raw sequencing read count for each analyte for a given sample well is divided by that well's internal control (IC) raw count. Second, to control for plate-to-plate variation,

the IC-normalized values for each analyte are divided by the analyte-specific median IC-normalized counts from the 3 inter-plate controls (IPCs) on the plate. Data is then rescaled and log₂-transformed to obtain the data in NPQ, which are approximately normally distributed values amenable to downstream statistical analysis.

Sensitivity & Detectability

The limit of detection (LOD), or the lowest concentration of the analyte that can be distinguished from the background signal of the assay, is calculated for each target as the mean plus three standard deviations of the 4 negative control (NC) wells' normalized reads. These values are rescaled and log-transformed to obtain LOD in NPQ. A maximum of one outlier NC value may be omitted. Median and interquartile ranges (IQR) for LOD were calculated across 17 runs (Table 3).

Target detectability is the percentage of samples above LOD. Detectability was assessed in 60 EDTA plasma and 430 CSF samples. In EDTA plasma, more than 95% of targets were detectable in at least 50% of samples, and in CSF, more than 83% of targets were detectable in at least 50% of samples (Table 3, Figure 1). Median and interquartile ranges (IQR) for LOD were calculated across 17 runs (Table 3).




Figure 1. Detectability was assessed in 22 healthy and 38 disease EDTA plasma samples. More than 95% of targets were detectable in at least 50% of samples.

Precision

Intra-assay precision, or repeatability, was measured to assess the variation in technical replicates within the same assay run; this is reported in Tables 1-3 as intra-plate coefficient of variation (CV). Inter-assay precision was measured to assess the variation in technical replicates across different assay runs or on different days; this is reported in Tables 1-3 as inter-plate CV. For each target, CV was determined using a variance component analysis model to assess the contribution of various factors to the total CV of the normalized reads. Six plasma and six CSF samples with 3 technical replicates each were measured across a set of 6 runs which included 1 reagent lot and 2 instruments across 6 days. Variance component analysis models were fit for each sample and target and included the factors instrument, inter-plate, and intra-plate (Tables 1-3). For each target, the estimated CV for each component was averaged across the 6 samples. Values below LOD and samples with average raw read counts below 100 were excluded from CV calculations.

Table 1: Across-target Median Coefficients of Variation

CV component	PLASMA	CSF
Intra-plate	10.60	10.94
Inter-plate	6.55	5.69

Table 2: Percentage of Targets with CV Below 30%

CV component	PLASMA	CSF
Intra-plate	98.40%	98.30%
Inter-plate	95.20%	94.80%

Cross-Reactivity

To assess cross-reactivity, targets were randomly assigned to two sets of 26 pools containing either four or five targets each, such that no two targets shared a pool for both sets. Counts were normalized using an internal control. Cross-reactivity for each target was quantified as $(\text{maximum non-target pool count} - \text{background}) / (\text{average target pool counts} - \text{background}) * 100$, where the background

was calculated as the median count across non-target pools. Cross reactivity to proteins outside the panel that have high homology to targeted proteins was also assessed. Cross-reactivity was only assessed for targets with commercially available recombinant antigen (Table 3, Figure 2).

Analysis of Cross Reactivity Potential in CNS Disease Panel 120




Figure 2. Heatmaps for each pool set show the percentage of target reads occurring in assigned target pools, on the diagonal, or non-target pools, in the off-diagonal cells. Most targets have cross-reactivity < 1%.

Table 3: Performance Validation Data by Target

Target	UniProt ID	Protein Name	Detectability (%)		CV (%)				LOD (NPQ) Median (IQR)	Cross Reactivity
			Plasma n=60	CSF n=430	Plasma		CSF			
					Intra	Inter	Intra	Inter		
Abeta38	P05067	Amyloid-beta precursor protein	93.3	99.8	19.3	15.5	9.3	5.2	5.4 (4.2, 6.2)	< 1%
Abeta40	P05067	Amyloid-beta precursor protein	93.3	99.5	21.0	5.8	9.9	5.1	4.8 (3.8, 5.8)	< 1%
Abeta42	P05067	Amyloid-beta precursor protein	80.0	99.8	22.4	17.5	6.7	11.8	10.4 (10.1, 10.7)	< 1%
ACHE	P22303	Acetylcholinesterase	100.0	100.0	10.4	4.2	8.8	5.7	3.0 (2.2, 4.2)	< 1%
AGRN	O00468	Agrin	100.0	100.0	9.4	6.8	5.7	8.1	9.0 (8.7, 9.3)	< 1%
ANXA5	P08758	Annexin A5	100.0	100.0	8.3	6.8	11.8	7.4	2.0 (1.8, 2.3)	< 1%
APOE	P02649	Apolipoprotein E	100.0	100.0	6.6	3.7	3.5	3.6	23.4 (22.3, 24.0)	< 1%
APOE4	P02649	Apolipoprotein E	50.0	52.6	8.4	3.1	7.2	4.8	0.0 (0.0, 0.5)	n/a
ARSA	P15289	Arylsulfatase A	100.0	25.8	6.9	14.9	14.6	35.6	6.3 (6.1, 6.4)	n/a
BACE1	P56817	Beta-secretase 1	100.0	100.0	9.8	5.6	6.2	4.2	9.1 (8.9, 9.3)	< 1%
BASP1	P80723	Brain abundant membrane attached signal protein 1	95.0	13.7	7.8	8.4	8.1	8.4	11.5 (11.3, 11.7)	n/a
BDNF	P23560	Brain-derived neurotrophic factor	100.0	5.8	5.7	3.8	n/a	n/a	4.2 (3.9, 4.5)	< 1%
CALB2	P22676	Calretinin	95.0	100.0	18.1	25.7	9.3	25.0	9.3 (9.1, 9.6)	< 1%
CCL11	P51671	Eotaxin	100.0	79.1	9.6	6.3	39.9	6.8	9.6 (9.4, 9.8)	< 1%
CCL13	Q99616	C-C motif chemokine 13	100.0	97.4	6.4	1.7	n/a	n/a	0.8 (0.0, 3.3)	< 1%
CCL17	Q92583	C-C motif chemokine 17	100.0	99.8	7.0	5.0	12.7	9.7	1.2 (1.0, 1.5)	< 1%
CCL2	P13500	C-C motif chemokine 2	100.0	100.0	28.2	7.1	16.5	7.6	6.5 (6.2, 6.9)	< 1%
CCL22	O00626	C-C motif chemokine 22	100.0	93.7	5.6	2.4	17.7	4.6	1.4 (0.0, 2.8)	< 1%
CCL26	Q9Y258	C-C motif chemokine 26	100.0	95.6	5.9	6.0	12.0	3.1	5.8 (5.5, 6.0)	< 1%
CCL3	P10147	C-C motif chemokine 3	100.0	100.0	12.4	6.0	12.7	1.0	5.4 (4.8, 5.7)	124.1% ^a
CCL4	P13236	C-C motif chemokine ligand 4	100.0	97.0	19.7	6.1	24.2	14.7	6.0 (5.1, 6.7)	661.2% ^b
CD40LG	P29965	CD40 ligand	100.0	98.6	9.5	8.2	n/a	n/a	2.0 (0.0, 3.9)	< 1%
CD63	P08962	CD63 antigen	100.0	100.0	7.4	2.4	11.7	3.3	7.3 (7.1, 7.5)	< 1%
CHI3L1	P36222	Chitinase-3-like protein 1	100.0	100.0	16.5	4.2	7.8	6.3	0.0 (0.0, 0.0)	< 1%
CHIT1	Q13231	Chitotriosidase-1	100.0	94.9	12.6	5.8	17.0	2.8	0.0 (0.0, 0.0)	< 1%
CNTN2	Q02246	Contactin-2	100.0	100.0	n/a	n/a	6.1	9.3	0.0 (0.0, 0.0)	< 1%
CRH	P06850	Corticotiberin	95.0	100.0	25.6	30.4	16.3	11.7	10.4 (10.2, 11.0)	< 1%
CRP	P02741	C-reactive protein	100.0	100.0	13.1	9.7	5.9	12.8	20.7 (19.9, 21.1)	< 1%
CSF2	P04141	Granulocyte-macrophage colony-stimulating factor	98.3	99.8	7.2	6.2	8.4	7.1	9.7 (9.5, 10.0)	< 1%
CST3	P01034	Cystatin-C	100.0	100.0	8.2	14.3	5.7	4.4	5.8 (5.4, 6.1)	< 1%
CX3CL1	P78423	Fractalkine	100.0	100.0	8.0	7.1	13.1	2.7	6.7 (6.5, 6.8)	< 1%
CXCL1	P09341	Growth-regulated alpha protein	100.0	99.1	12.6	5.7	17.5	3.1	7.3 (7.0, 7.5)	< 1%
CXCL10	P02778	C-X-C motif chemokine 10	100.0	98.8	23.5	8.4	12.2	6.4	0.0 (0.0, 0.0)	< 1%
CXCL8	P10145	Interleukin-8, IL8	95.0	100.0	12.7	12.8	6.0	8.7	10.3 (10.2, 10.4)	< 1%
DDC	P20711	Aromatic-L-amino-acid decarboxylase	100.0	99.8	4.6	4.3	6.8	3.9	2.7 (2.3, 3.3)	< 1%
ENO2	P09104	Gamma-enolase	100.0	100.0	4.9	20.7	5.2	9.4	3.1 (2.7, 3.6)	< 1%
FABP3	P05413	Fatty acid-binding protein, heart	100.0	100.0	6.6	1.0	6.6	2.7	3.3 (2.7, 3.7)	< 1%
FCN2	Q15485	Ficolin-2	100.0	67.0	11.1	25.6	n/a	n/a	0.0 (0.0, 0.0)	< 1%
FGF2	P09038	Fibroblast growth factor 2	96.7	88.8	14.8	1.9	19.4	8.1	9.6 (9.5, 9.7)	< 1%
FLT1	P17948	Vascular endothelial growth factor receptor 1	100.0	100.0	17.1	10.1	14.2	8.5	8.1 (7.7, 8.5)	< 1%
FOLR1	P15328	Folate receptor alpha	100.0	100.0	15.1	4.4	8.1	4.1	2.6 (0.0, 3.9)	< 1%
GDF15	Q99988	Growth/differentiation factor 15	100.0	92.1	12.5	2.1	n/a	n/a	0.0 (0.0, 0.0)	< 1%
GDI1	P31150	Rab GDP dissociation inhibitor alpha	73.3	86.7	24.3	34.0	9.7	30.7	11.5 (11.2, 11.8)	< 1%
GDNF	P39905	Glial cell line-derived neurotrophic factor	81.7	1.6	10.1	14.1	9.0	0.0	9.6 (9.3, 9.7)	< 1%
GFAP	P14136	Glial fibrillary acidic protein	100.0	100.0	10.1	5.8	5.5	8.8	8.4 (8.2, 8.8)	< 1%
GOT1	P17174	Aspartate aminotransferase, cytoplasmic	100.0	99.5	16.9	11.2	14.9	11.0	10.0 (9.9, 10.2)	< 1%

Table 3: Performance Validation Data by Target

Target	UniProt ID	Protein Name	Detectability (%)		CV (%)				LOD (NPQ) Median (IQR)	Cross Reactivity
			Plasma n=60	CSF n=430	Plasma		CSF			
					Intra	Inter	Intra	Inter		
HBA1	P69905	Hemoglobin subunit alpha	100.0	45.1	14.0	0.0	8.1	41.2	0.0 (0.0, 2.4)	< 1%
HTT	P42858	Huntingtin	100.0	99.3	7.2	6.8	11.0	3.1	7.5 (7.3, 7.7)	< 1%
ICAM1	P05362	Intercellular adhesion molecule 1	100.0	95.6	9.9	4.7	n/a	n/a	0.0 (0.0, 0.0)	< 1%
IFNG	P01579	Interferon gamma	100.0	84.0	10.9	6.6	14.0	1.4	6.7 (6.3, 7.1)	< 1%
IGF1R	P08069	Insulin-like growth factor 1 receptor	98.3	100.0	10.1	6.3	6.8	6.3	11.4 (11.3, 11.6)	< 1%
IGFBP7	Q16270	Insulin-like growth factor-binding protein 7	100.0	100.0	9.2	3.6	6.6	3.8	7.5 (7.2, 7.7)	< 1%
IL10	P22301	Interleukin-10	100.0	99.8	9.4	9.4	12.9	3.1	6.5 (6.3, 6.7)	< 1%
IL12p70	P29459_P29460	Interleukin-12 subunit beta_Interleukin-12 subunit alpha	100.0	95.3	10.8	9.5	17.6	4.7	8.5 (8.2, 8.9)	< 1%
IL13	P35225	Interleukin-13	100.0	74.7	25.8	19.1	18.3	10.9	8.7 (8.5, 9.0)	< 1%
IL15	P40933	Interleukin-15	100.0	100.0	14.2	6.7	13.3	2.6	7.4 (7.1, 7.9)	< 1%
IL16	Q14005	Pro-interleukin-16	100.0	100.0	5.8	1.7	8.2	3.4	3.9 (3.7, 4.1)	< 1%
IL17A	Q16552	Interleukin-17A	98.3	1.6	15.3	10.1	46.0	3.8	10.0 (9.8, 10.0)	< 1%
IL18	Q14116	Interleukin-18	100.0	100.0	5.7	4.2	19.2	3.7	4.1 (4.0, 4.6)	< 1%
IL1B	P01584	Interleukin-1 beta	60.0	5.6	6.5	2.1	n/a	n/a	10.9 (10.6, 11.2)	< 1%
IL2	P60568	Interleukin-2	100.0	47.4	24.1	4.8	20.9	7.7	8.0 (7.7, 8.4)	< 1%
IL33	O95760	Interleukin 33	100.0	44.2	30.3	30.2	27.7	11.8	10.6 (10.4, 11.4)	< 1%
IL4	P05112	Interleukin-4	96.7	11.2	34.2	31.8	24.3	24.0	9.3 (9.1, 9.5)	< 1%
IL5	P05113	Interleukin-5	100.0	100.0	18.0	5.3	9.4	3.1	6.1 (6.0, 6.4)	< 1%
IL6	P05231	Interleukin-6	100.0	100.0	16.1	5.0	8.7	2.4	8.1 (8.1, 8.3)	< 1%
IL6R	P08887	Interleukin-6 receptor subunit alpha	100.0	97.7	15.3	6.8	n/a	n/a	0.0 (0.0, 4.9)	< 1%
IL7	P13232	Interleukin-7	100.0	100.0	10.4	3.4	11.1	3.5	8.1 (8.0, 8.3)	< 1%
IL9	P15248	Interleukin-9	100.0	100.0	23.2	3.2	12.1	2.9	0.0 (0.0, 4.0)	< 1%
KDR	P35968	Vascular endothelial growth factor receptor 2	100.0	97.2	8.9	3.3	24.4	0.0	0.0 (0.0, 2.3)	< 1%
KLK6	Q92876	Kallikrein-6	100.0	100.0	20.2	5.2	4.8	12.4	6.7 (5.9, 7.0)	< 1%
MDH1	P40925	Malate dehydrogenase, cytoplasmic	100.0	100.0	10.8	7.8	10.9	3.8	6.5 (6.3, 6.7)	< 1%
MME	P08473	Membrane metalloendopeptidase	100.0	16.5	17.3	18.1	n/a	n/a	0.9 (0.6, 1.4)	n/a
MSLN	Q13421	Mesothelin	100.0	100.0	8.8	4.7	13.3	3.8	5.3 (4.8, 5.9)	n/a
NEFH	P12036	Neurofilament heavy polypeptide	90.0	100.0	29.8	50.4	8.1	36.8	13.3 (12.9, 13.8)	n/a
NEFL	P07196	Neurofilament light polypeptide	100.0	100.0	9.9	8.0	4.9	6.3	7.6 (7.4, 7.8)	< 1%
NGF	P01138	Beta-nerve growth factor	100.0	94.4	12.0	4.4	16.3	1.9	6.1 (5.7, 6.3)	< 1%
NPTX1	Q15818	Neuronal pentraxin-1	96.7	100.0	19.1	30.8	6.1	33.3	10.7 (10.4, 10.9)	1.0% ^c
NPTX2	P47972	Neuronal pentraxin-2	100.0	100.0	8.3	4.9	7.1	7.2	9.3 (9.2, 9.4)	< 1%
NPTXR	O95502	Neuronal pentraxin receptor	100.0	100.0	22.8	11.3	4.8	11.0	8.1 (7.8, 8.6)	< 1%
NPY	P01303	Neuropeptide Y	100.0	99.5	9.0	8.2	6.8	9.9	4.7 (4.4, 5.2)	n/a
NRGN	Q92686	Neurogranin	96.7	65.6	7.0	8.5	7.9	6.3	8.7 (8.6, 8.8)	< 1%
Oligo-SNCA	P37840	Alpha-synuclein	100.0	17.9	19.4	15.5	11.9	0.0	10.1 (9.9, 10.4)	30.1% ^d
PARK7	Q99497	Protein/nucleic acid deglycase DJ-1	100.0	91.4	10.8	9.5	15.1	12.6	8.2 (7.8, 8.3)	< 1%
PDGFRB	P09619	Platelet-derived growth factor receptor beta	100.0	100.0	7.3	1.2	19.4	2.4	0.0 (0.0, 0.0)	< 1%
PDLIM5	Q96HC4	PDZ and LIM domain 5	100.0	6.3	12.2	18.7	14.6	9.3	7.9 (7.8, 8.1)	< 1%
PGF	P49763	Placenta growth factor	100.0	100.0	5.9	3.5	6.5	2.6	9.6 (9.4, 9.7)	n/a
PGK1	P00558	Phosphoglycerate kinase 1	100.0	88.1	7.7	15.3	9.3	9.8	2.8 (2.4, 3.0)	n/a
POSTN	Q15063	Periostin	100.0	95.6	7.3	1.8	n/a	n/a	1.3 (0.0, 2.5)	< 1%
PRDX6	P30041	Peroxiredoxin-6	100.0	97.2	10.9	3.2	14.3	5.7	6.1 (5.8, 6.3)	< 1%
PSEN1	P49768	Presenilin 1	91.7	99.5	14.2	7.3	11.0	4.0	10.2 (9.9, 10.8)	< 1%
pSNCA-S129	P37840	Alpha-synuclein	100.0	47.9	6.3	7.7	14.1	9.5	8.4 (8.2, 8.6)	< 1%
pTARDBP-S409	Q13148	TAR DNA-binding protein 43	68.3	7.7	14.0	20.5	12.5	18.4	10.2 (10.1, 10.5)	< 1%

Table 3: Performance Validation Data by Target

Target	UniProt ID	Protein Name	Detectability (%)		CV (%)				LOD (NPQ) Median (IQR)	Cross Reactivity
			Plasma n=60	CSF n=430	Plasma		CSF			
					Intra	Inter	Intra	Inter		
pTau-T181	P10636	Microtubule-associated protein tau	100.0	100.0	8.7	9.6	6.8	4.9	10.7 (10.6, 10.8)	< 1%
pTau-T217	P10636	Microtubule-associated protein tau	85.0	99.5	16.6	13.2	7.4	4.3	11.2 (11.1, 11.3)	< 1%
pTau-T231	P10636	Microtubule-associated protein tau	100.0	99.8	11.2	7.0	3.6	4.6	10.4 (10.3, 10.6)	< 1%
PTN	P21246	Pleiotrophin	71.7	99.5	25.0	2.7	13.7	32.9	5.0 (4.7, 5.1)	< 1%
REST	Q13127	RE1 silencing transcription factor	100.0	74.7	10.8	3.5	23.2	0.7	7.8 (7.5, 8.1)	< 1%
RUVBL2	Q9Y230	RuvB like AAA ATPase 2	86.7	53.7	7.8	8.1	6.4	8.3	11.0 (10.8, 11.1)	< 1%
S100A12	P80511	Protein S100-A12	100.0	27.0	6.3	8.3	25.9	7.2	6.1 (5.9, 6.4)	< 1%
S100B	P04271	S100 calcium binding protein B	100.0	100.0	14.1	10.2	5.9	8.3	9.7 (9.5, 9.8)	< 1%
SAA1	P0DJ18	Serum amyloid A-1 protein	100.0	29.8	7.7	5.8	n/a	n/a	1.8 (1.2, 2.7)	< 1%
SFRP1	Q8N474	Secreted frizzled-related protein 1	95.0	100.0	16.7	9.0	13.8	15.8	11.6 (11.3, 11.8)	< 1%
SFTPD	P35247	Pulmonary surfactant-associated protein D	100.0	98.4	10.6	4.5	16.4	5.9	6.5 (6.5, 6.7)	< 1%
SLIT2	O94813	Slit homolog 2 protein	100.0	100.0	5.8	1.2	7.5	3.5	10.0 (10.0, 10.1)	< 1%
SMOC1	Q9H4F8	SPARC-related modular calcium-binding protein 1	100.0	100.0	10.2	10.3	9.1	11.4	7.6 (7.2, 7.8)	< 1%
SNAP25	P60880	Synaptosomal-associated protein 25	100.0	96.0	6.6	7.2	6.7	12.0	11.9 (11.8, 12.0)	< 1%
SNCA	P37840	Alpha-synuclein	100.0	99.3	4.6	2.3	16.2	11.2	4.4 (4.2, 4.6)	< 1%
SNCB	Q16143	Synuclein beta	21.7	88.8	14.8	28.3	7.1	11.1	11.4 (11.3, 11.4)	< 1%
SOD1	P00441	Superoxide dismutase [Cu-Zn]	93.3	100.0	17.7	0.8	12.3	2.0	0.0 (0.0, 4.9)	< 1%
SQSTM1	Q13501	Sequestosome-1	100.0	100.0	13.4	10.4	13.1	2.6	0.0 (0.0, 2.3)	< 1%
TAFA5	Q7Z5A7	Chemokine-like protein TAFA-5	95.0	100.0	21.6	11.8	5.0	3.2	7.3 (6.8, 7.4)	< 1%
TARDBP	Q13148	TAR DNA-binding protein 43	100.0	94.7	6.3	4.7	8.8	4.6	4.8 (4.8, 5.1)	n/a
TEK	Q02763	Angiopoietin-1 receptor	100.0	100.0	6.6	3.2	17.5	10.6	1.5 (1.3, 2.1)	< 1%
TIMP3	P35625	Metalloproteinase inhibitor 3	100.0	100.0	6.8	5.2	16.0	2.3	4.1 (3.9, 4.3)	1.0% ^e
TNF	P01375	Tumor necrosis factor	100.0	92.6	6.2	8.4	12.8	0.0	9.4 (9.1, 9.7)	< 1%
TREM1	Q9NP99	Triggering receptor expressed on myeloid cells 1	100.0	99.8	13.8	5.8	15.0	2.9	5.9 (4.4, 6.5)	< 1%
TREM2	Q9NZC2	Triggering receptor expressed on myeloid cells 2	100.0	100.0	9.1	10.4	8.0	2.6	0.0 (0.0, 0.0)	< 1%
tTau	P10636	Microtubule-associated protein tau	100.0	100.0	10.8	13.3	6.2	15.7	7.8 (7.5, 7.9)	< 1%
UBB	P0CG47	Polyubiquitin-B	48.3	3.7	9.3	15.9	2.3	1.8	12.4 (12.4, 12.6)	n/a
UCHL1	P09936	Ubiquitin carboxyl-terminal hydrolase isozyme L1	6.7	77.0	5.0	0.0	5.6	15.6	12.3 (12.3, 12.4)	< 1%
VCAM1	P19320	Vascular cell adhesion protein 1	100.0	100.0	10.8	4.0	23.6	2.0	0.0 (0.0, 0.0)	< 1%
VEGFA	P15692	Vascular endothelial growth factor A	100.0	100.0	8.0	1.1	5.3	5.0	9.3 (9.0, 9.4)	< 1%
VEGFD	O43915	Vascular endothelial growth factor D	100.0	64.9	9.7	3.1	9.3	5.2	10.6 (10.4, 10.8)	< 1%
VEGF	O15240	VEGF nerve growth factor inducible	88.3	18.8	16.2	5.5	18.5	7.7	10.8 (10.7, 11.0)	n/a
VSNL1	P62760	Visinin-like protein 1	100.0	100.0	8.4	3.1	6.6	5.2	9.5 (9.2, 9.7)	10.1% ^f
YWHAG	P61981	Tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein gamma	36.7	16.0	19.4	24.0	13.2	12.7	12.6 (12.4, 12.8)	< 1%
YWHAZ	P63104	14-3-3 protein zeta/delta	63.3	0.5	n/a	n/a	12.3	4.5	11.2 (10.9, 11.3)	< 1%

a. Cross-reactivity with CCL3L1 and CCL4L1, which have 95% and 63% homology with CCL3. CCL3L1 and CCL4L1 are not in the CNS panel.

b. Cross-reactivity with CCL4L1, which has 97% homology with CCL4. CCL4L1 is not in the CNS panel.

c. Cross-reactivity with SOD1.

d. Cross-reactivity with pSNCA-129.

e. Cross-reactivity with VGF.

f. Cross-reactivity with HPCAL4, which has 89% homology with VSNL1. HPCAL4 is not in the CNS panel.

NULISAseq™ CNS Disease Panel 120

Ordering Information

NULISAseq Panel

Product Name	Plate Format	Sample Type	Catalog Number
NULISAseq CNS Disease Panel 120	96	plasma/serum/CSF	800104

Consumables & Buffers

Product Name	Qty	Catalog Number
NULISA Wash Buffer (3L)	3L	801035

Instrument

Product Name	Qty	Catalog Number
Alamar ARGO HT System	1	800101

Alamar Biosciences, Inc.
47071 Bayside Parkway
Fremont, CA 94538

T +1 (510) 626-9888
E info@alamarbio.com

Visit [AlamarBio.com](https://www.alamarbio.com) to learn more.

FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.
©2025 Alamar Biosciences, Inc. All rights reserved. Alamar, NULISA, NULISAseq and ARGO are trademarks of Alamar Biosciences, Inc. All other trademarks and/or service marks not owned by Alamar that appear are the property of their respective owners.
M1023-0225.1

